## Statement of Standalone Unaudited Results for the Quarter Ended 31/12/2016

(In lacs)

	Particulars	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 Months Ended	Year to date
		(31-12-2016)	(30-09-2016)	(31-12-2015)	(31-12-2016)	(31-12-2015)	figures for
							current period
							ended
-			<del></del>				(31/03/2016)
_		(Manualtana)	(the analysis)	/ttensaltenst	Attan offered	(Unaudited)	(Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Addited)
1	Income from operations	400.04	404.00	25.50	24707	450.53	400.40
	(a) Net sales/income from operations	132.94	184.93	36.58	317.87	158.62	482.40
	(Net of excise duty)	SALMONDA .		2000			
	(b) Other operating income	0.00	0.00	0.00	0.00	100.00	
	Total income from operations (net)	132.94	184.93	36.58	317.87	258.62	482.4
2	Expenses						
	(a) Cost of materials consumed	26.84	43.31	20.71	70.15	65.63	77.30
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	.0.00	0.00
	(c) Changes in inventories of finished goods,	-0.45	3.62	-31.53	3.17	1.58	91.20
	work-in-progress and stock-in-trade						
	(d) Employee benefits expense	35.09	49.51	27.29	84.60	88.99	115.80
	(e) Depreciation and amortisation expense	9.25	24.35	15.00	33.60	45.00	44.80
	(f) Other expenses (Any item exceeding	48.22	30.16	11.88	78.38	45.49	79.40
	10% of the total expenses relating to						
	continuing operations to be shown						
	separately)						
	Total expenses	118.95	150.95	43.35	269.90	246.69	408 50
3	Profit / (Loss) from operations before other	13.99	33.98	(6.77)	47.97	11.93	73.90
3	income, finance costs and exceptional	13.55	00.00	(0.77)	41.91	11.55	70.00
-							
-	items (1-2)	0.00	0.40	0.75	2.20		
-	Other income	0.96	2.43	0.63	3,39	1.94	6.8
5	Profit / (Loss) from ordinary activities	14.95	36.41	(6.14)	51.36	13.87	80.70
	before finance costs and exceptional items						
	(3 + 4)						
6	Finance costs	0.00	0.00	0.00	0.00	0.00	0.1
7	Profit / (Loss) from ordinary activities after	14.95	36.41	(6.14)	51.36	13.87	80 60
	finance costs but before exceptional items						
	(5 + 6)						
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	-40.6
9	Profit / (Loss) from ordinary activities	14.95	36.41	(6.14)	51.36	13.87	40.00
	before tax						
	(7 + 8)						
10	Tax expense - Provision for taxation	4.50	11.50	0.00	16.00	0.00	23 1
	Net Profit / (Loss) from ordinary activities	10.45	24.91	(6.14)	35.36	13.87	16.90
	after tax (9 + 10)	10.75	6.1.01	10.117	00.00	10.01	10.00
12		0.00	0.00	0.00	0.00	0.00	0.00
12	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
12	Net Profit / (Loss) for the period (11 + 12)	10.4E	24.04	(0.44)	25.26	42.07	40.00
-		10,45	24.91	(6.14)	35.36	13.87	16.90
_	Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
	Minority interest *	0.00	0.00	0.00	0,00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority	10.45	24.91	(6.14)	35.36	13.87	16.90
	interest and share of profit / (loss) of						
	associates (13 + 14 + 15) *						
17	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57	156.57
	(Face Value of the Share shall be indicated)						
18	Reserve excluding Revaluation Reserves as:	0.00	0.00	0.00	0.00	0,00	0.00
19.i	per balance sheet of previous accounting year						
	Earnings per share (before extraordinary						
	items)						
	(of Rs 10/- each) (not annualised):						
	(a) Basic	0.07	0.16	(0.04)	0.23	0.09	0.11
	(b) Diluted	0.07	0.16	(0:04)	0.23	0.09	0.11
9.ii	Earnings per share (after extraordinary			(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)			
	items)						
	(of Rs. 10/- each) (not annualised):						
_	(a) Basic	0.07	0.16	-0.04	0.23	0.09	0.11
	(b) Diluted	0.07	0.16	-0.04	0.23	0.09	
	ATA	1,949,6	0.10	-0,04	4.63	0.03	0.11

Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th February 2017

- 2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.
- 3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

Place : Ahmedabad Date : 14/02/2017



## SHUKRA PHARMACEUTICALS LTD Regd. Off.: 3rd Floor, Dev House, Judges Bunglow Road, Bodak Dev, Ahmedabad - 54 CIN: L24231GJ1993PLC019079 PART II Quarter Ended 31/12/2016 3 Months Ended 3 Months Ended 3 Months Ende9 Months Ended 9 Months Ended Year to date Particulars (31-12-2016) (30-09-2016) (31-12-2015) (31-12-2016) (31-12-2015) figures for current period ended (31/03/2016) PARTICULARS OF SHAREHOLDING 1 Public shareholding 769770 769770 769770 769770 769770 769770 Number of shares Percentage of shareholding 49.17% 49.17% 49.17% 49.17% 49.17% 49.17% 2 Promoters and Promoter Group Shareholding \*\* a) Pledged/Encumbered 0.00 0.00 0.00 0.00 0.00 0.00 Number of shares 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% Percentage of shares (as a % of the total shareholding of promoter and promoter 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% Percentage of shares (as a % of the total share capital of the company) b) Non-encumbered 795905 795905 795905 795905 795905 Number of shares 795905 100.00% Percentage of shares (as a % of the total 100.00% 100.00% 100.00% 100.00% 100.00% shareholding of the Promoter and Promoter group)

50.83%

50.83%

50.83%

	Particulars	3 months ended 31/12/2016	
В	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter		
	Received during the quarter		
	Disposed of during the quarter		
	Remaining unresolved at the end of the quarter		

Percentage of shares (as a % of the total

share capital of the company)

50.83%

Place: Ahmedabad

Date: 14/02/2017

For, Shukra Pharmaceauticals Limited For Shukra Pharmaceuticals Limited

50.83%

Director/Authorised Signatury

DIN: 07032481

50.83%

## SHUKRA PHARMACEUTICALS LIMITED

STATEMENT OF ASSETS AND LIABILITIES	STANDALONE		
	As at current period ended 31-12-2016	As at current year end 31-3-2016	
	(Unaudited)	(Audited)	
A EQUITY AND LIABILITIES			
1 SHAREHOLDERS FUNDS			
(a) Share Capital	156.57	156.57	
(b) Reserves and surplus	1271.19	1250.78	
(c)Money received against share warrant			
SHAREHOLDERS FUNDS	1427.76	1407.35	
2 SHARE APPLICATION MONEY PENDING ALLOTMENT			
3 NON - CUURENT LIABLITIES			
(a) Long-term borrowing	0	0	
(b) Defered tax liabilities (net)	244.14	244.14	
(c )Other long-term liabilities		0	
(d) long-term provisions		0	
NON - CURENT LIABLITIES	244.1	244.1	
4 CURRENT LIABILITIES	**************************************		
(a) Short-term borrowing	3.6	3.6	
(b) Trade payables	22.87	25.55	
(c ) Other current laibilities	0	0	
(d) Short- term provision	17.11	0	
CURRENT LIABILITIES	43.58	29.15	
TOTAL EQUITY AND LIABILITIES	1715.48	1681	
B ASSETS			
1 NON - CURRENT ASSETS			
(a) Fixed assets	1130.91	1135.6	
(b) Non- current investments	4.15	4.15	
(c ) Deferred tax assets (net)		0	
(d) long-term loans and advances		0	
(e) Other non-current assets	8.27	9.27	
NON - CURRENT ASSETS			
2 CURRENT ASSETS			
(a) Currents investments	0	0	
(b) Inventories	40.22	43.65	
(c ) Trade receivables	109.48		
(d) Cash and cash equivalents	119.54		
(e) Short-term loans and advances	262.39		
(f) Other current asets	40.52	47.89	
CURRENT ASSETS		531.6	
TOTAL ASSETS			

For Shukra Pharmaceuticals Limited

Director/Authorised Signatory